Advertisement
Screener

Protagonist Therapeutics, Inc (PTGX) Accumulated Other Comprehensive Income

2.8 / 5 stars · 68/120 Roast Me

Protagonist Therapeutics, Inc Accumulated Other Comprehensive Income

Protagonist Therapeutics, Inc (PTGX) had Accumulated Other Comprehensive Income of -$828.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-05.

Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent

us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-05

  • 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$828.00K.
  • 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$269.00K.
  • 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $641.00K.
  • 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $525.00K.
Period endAccumulated Other Comprehensive Income (Loss), Net of Tax
2026-06-30-$828.00K
10-Q · filed 2026-08-05
2026-03-31-$269.00K
10-Q · filed 2026-05-05
2025-12-31$641.00K
10-Q · filed 2026-08-05
2025-09-30$525.00K
10-Q · filed 2025-11-06
2025-06-30-$15.00K
10-Q · filed 2025-08-06
2025-03-31$85.00K
10-Q · filed 2025-05-06
2024-12-31-$82.00K
10-K · filed 2026-02-25
2024-09-30$1.34M
10-Q · filed 2024-11-07
2024-06-30-$249.00K
10-Q · filed 2024-08-06
2024-03-31-$229.00K
10-Q · filed 2024-05-07
2023-12-31-$105.00K
10-K · filed 2025-02-21
2023-09-30-$170.00K
10-Q · filed 2023-11-02
2023-06-30-$198.00K
10-Q · filed 2023-08-03
2023-03-31-$122.00K
10-Q · filed 2023-05-04
2022-12-31-$359.00K
10-K · filed 2024-02-27
2022-09-30-$480.00K
10-Q · filed 2022-11-08
2022-06-30-$720.00K
10-Q · filed 2022-08-04
2022-03-31-$472.00K
10-Q · filed 2022-05-05
2021-12-31-$299.00K
10-K · filed 2023-03-15
2021-09-30-$204.00K
10-Q · filed 2021-11-03
2021-06-30-$59.00K
10-Q · filed 2021-08-04
2021-03-31-$33.00K
10-Q · filed 2021-05-04
2020-12-31$28.00K
10-K · filed 2022-02-28
2020-09-30-$88.00K
10-Q · filed 2020-11-04
2020-06-30-$208.00K
10-Q · filed 2020-08-06
2020-03-31$107.00K
10-Q · filed 2020-05-07
2019-12-31-$221.00K
10-K · filed 2021-03-10
2019-09-30-$154.00K
10-Q · filed 2019-11-06
2019-06-30-$167.00K
10-Q · filed 2019-08-07
2019-03-31-$189.00K
10-Q · filed 2019-05-08
2018-12-31-$233.00K
10-K · filed 2020-03-10
2018-09-30-$103.00K
10-Q · filed 2018-11-06
2018-06-30-$86.00K
10-Q · filed 2018-08-07
2018-03-31-$72.00K
10-Q · filed 2018-05-09
2017-12-31-$6.00K
10-K · filed 2019-03-12
2017-09-30$100.00K
10-Q · filed 2017-11-07
2017-06-30$3.00K
10-Q · filed 2017-08-08
2017-03-31-$22.00K
10-Q · filed 2017-05-10
2016-12-31-$245.00K
10-K · filed 2018-03-07
2016-09-30-$24.00K
10-Q · filed 2016-11-14
2016-06-30-$101.00K
10-Q · filed 2016-09-15
2015-12-31-$102.00K
10-K · filed 2017-03-07

Similar stocks

Stock NameCountryMarket CapPE Ratio
TG THERAPEUTICS, INC. (TGTX)United States$8.805B19.05
CYTOKINETICS INC (CYTK)United States$9.130B-11.86
ARROWHEAD PHARMACEUTICALS, INC. (ARWR)United States$9.331B-42.28
Praxis Precision Medicines, Inc. (PRAX)United States$7.884B-27.60
Structure Therapeutics Inc. (GPCR)United States$7.710B-53.41
Spyre Therapeutics, Inc. (SYRE)United States$7.685B-43.69
Axsome Therapeutics, Inc. (AXSM)United States$10.274B-66.82
IONIS PHARMACEUTICALS INC (IONS)United States$7.277B-23.25
Alkermes plc. (ALKS)$6.844B132.74
RHYTHM PHARMACEUTICALS, INC. (RYTM)United States$6.771B-37.20